MovDisordV3, PascalFrancis, Corpus, bibRecord, 003210

Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study

Identifieur interne : 003210 ( PascalFrancis/Corpus ); précédent : 003209; suivant : 003211

Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study

Auteurs : G. Meco ; A. Alessandri ; P. Giustini ; V. Bonifati

Source :

Movement disorders [ 0885-3185 ] ; 1997.

RBID : Pascal:97-0412076

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Psychose, Rispéridone, Antipsychotique, Trouble cognition, Chimiothérapie, Traitement, Homme, Etude longitudinale, Dose faible.

English descriptors

KwdEn :
- Antipsychotic, Chemotherapy, Cognitive disorder, Follow up study, Human, Low dose, Parkinson disease, Psychosis, Risperidone, Treatment.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 12`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study`
A11	`01`	`1`		`@1 MECO (G.)`
A11	`02`	`1`		`@1 ALESSANDRI (A.)`
A11	`03`	`1`		`@1 GIUSTINI (P.)`
A11	`04`	`1`		`@1 BONIFATI (V.)`
A14	`01`			`@1 Department of Neurological Sciences, "La Sapienza" University @2 Roma @3 ITA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut.`
A20				`@1 610-612`
A21				`@1 1997`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000067729910220`
A44				`@0 0000 @1 © 1997 INIST-CNRS. All rights reserved.`
A45				`@0 9 ref.`
A47	`01`	`1`		`@0 97-0412076`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C02	`01`	`X`		`@0 002B02B03`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Psychose @5 04`
C03	`02`	`X`	`ENG`	`@0 Psychosis @5 04`
C03	`02`	`X`	`SPA`	`@0 Psicosis @5 04`
C03	`03`	`X`	`FRE`	`@0 Rispéridone @2 NK @2 FR @5 07`
C03	`03`	`X`	`ENG`	`@0 Risperidone @2 NK @2 FR @5 07`
C03	`03`	`X`	`SPA`	`@0 Risperidona @2 NK @2 FR @5 07`
C03	`04`	`X`	`FRE`	`@0 Antipsychotique @5 08`
C03	`04`	`X`	`ENG`	`@0 Antipsychotic @5 08`
C03	`04`	`X`	`SPA`	`@0 Antipsicótico @5 08`
C03	`05`	`X`	`FRE`	`@0 Trouble cognition @5 10`
C03	`05`	`X`	`ENG`	`@0 Cognitive disorder @5 10`
C03	`05`	`X`	`SPA`	`@0 Trastorno cognitivo @5 10`
C03	`06`	`X`	`FRE`	`@0 Chimiothérapie @5 16`
C03	`06`	`X`	`ENG`	`@0 Chemotherapy @5 16`
C03	`06`	`X`	`SPA`	`@0 Quimioterapia @5 16`
C03	`07`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`07`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`07`	`X`	`GER`	`@0 Aufbereiten @5 17`
C03	`07`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`08`	`X`	`FRE`	`@0 Homme @5 20`
C03	`08`	`X`	`ENG`	`@0 Human @5 20`
C03	`08`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`09`	`X`	`FRE`	`@0 Etude longitudinale @5 23`
C03	`09`	`X`	`ENG`	`@0 Follow up study @5 23`
C03	`09`	`X`	`SPA`	`@0 Estudio longitudinal @5 23`
C03	`10`	`X`	`FRE`	`@0 Dose faible @5 24`
C03	`10`	`X`	`ENG`	`@0 Low dose @5 24`
C03	`10`	`X`	`SPA`	`@0 Dosis débil @5 24`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`06`	`X`	`FRE`	`@0 Psychopathologie @5 45`
C07	`06`	`X`	`ENG`	`@0 Psychopathology @5 45`
C07	`06`	`X`	`SPA`	`@0 Psicopatología @5 45`
N21				`@1 251`

Format Inist (serveur)

NO :	PASCAL 97-0412076 INIST
ET :	Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study
AU :	MECO (G.); ALESSANDRI (A.); GIUSTINI (P.); BONIFATI (V.)
AF :	Department of Neurological Sciences, "La Sapienza" University/Roma/Italie (1 aut., 2 aut., 3 aut., 4 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1997; Vol. 12; No. 4; Pp. 610-612; Bibl. 9 ref.
LA :	Anglais
CC :	002B02B03
FD :	Parkinson maladie; Psychose; Rispéridone; Antipsychotique; Trouble cognition; Chimiothérapie; Traitement; Homme; Etude longitudinale; Dose faible
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Psychopathologie
ED :	Parkinson disease; Psychosis; Risperidone; Antipsychotic; Cognitive disorder; Chemotherapy; Treatment; Human; Follow up study; Low dose
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Psychopathology
GD :	Aufbereiten
SD :	Parkinson enfermedad; Psicosis; Risperidona; Antipsicótico; Trastorno cognitivo; Quimioterapia; Tratamiento; Hombre; Estudio longitudinal; Dosis débil
LO :	INIST-20953.354000067729910220
ID :	97-0412076

Links to Exploration step

Pascal:97-0412076

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study</title>
<author><name sortKey="Meco, G" sort="Meco, G" uniqKey="Meco G" first="G." last="Meco">G. Meco</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, "La Sapienza" University</s1>
<s2>Roma</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Alessandri, A" sort="Alessandri, A" uniqKey="Alessandri A" first="A." last="Alessandri">A. Alessandri</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, "La Sapienza" University</s1>
<s2>Roma</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Giustini, P" sort="Giustini, P" uniqKey="Giustini P" first="P." last="Giustini">P. Giustini</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, "La Sapienza" University</s1>
<s2>Roma</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bonifati, V" sort="Bonifati, V" uniqKey="Bonifati V" first="V." last="Bonifati">V. Bonifati</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, "La Sapienza" University</s1>
<s2>Roma</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">97-0412076</idno>
<date when="1997">1997</date>
<idno type="stanalyst">PASCAL 97-0412076 INIST</idno>
<idno type="RBID">Pascal:97-0412076</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003210</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study</title>
<author><name sortKey="Meco, G" sort="Meco, G" uniqKey="Meco G" first="G." last="Meco">G. Meco</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, "La Sapienza" University</s1>
<s2>Roma</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Alessandri, A" sort="Alessandri, A" uniqKey="Alessandri A" first="A." last="Alessandri">A. Alessandri</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, "La Sapienza" University</s1>
<s2>Roma</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Giustini, P" sort="Giustini, P" uniqKey="Giustini P" first="P." last="Giustini">P. Giustini</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, "La Sapienza" University</s1>
<s2>Roma</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bonifati, V" sort="Bonifati, V" uniqKey="Bonifati V" first="V." last="Bonifati">V. Bonifati</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurological Sciences, "La Sapienza" University</s1>
<s2>Roma</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1997">1997</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antipsychotic</term>
<term>Chemotherapy</term>
<term>Cognitive disorder</term>
<term>Follow up study</term>
<term>Human</term>
<term>Low dose</term>
<term>Parkinson disease</term>
<term>Psychosis</term>
<term>Risperidone</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Psychose</term>
<term>Rispéridone</term>
<term>Antipsychotique</term>
<term>Trouble cognition</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Homme</term>
<term>Etude longitudinale</term>
<term>Dose faible</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>12</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MECO (G.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>ALESSANDRI (A.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>GIUSTINI (P.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BONIFATI (V.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurological Sciences, "La Sapienza" University</s1>
<s2>Roma</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>610-612</s1>
</fA20>
<fA21><s1>1997</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000067729910220</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1997 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>9 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>97-0412076</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02B03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Psychose</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Psychosis</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Psicosis</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Rispéridone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Risperidone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Risperidona</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antipsychotique</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antipsychotic</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antipsicótico</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Trouble cognition</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Cognitive disorder</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Trastorno cognitivo</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>16</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Etude longitudinale</s0>
<s5>23</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Follow up study</s0>
<s5>23</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Estudio longitudinal</s0>
<s5>23</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Dose faible</s0>
<s5>24</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Low dose</s0>
<s5>24</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Dosis débil</s0>
<s5>24</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Psychopathologie</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Psychopathology</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Psicopatología</s0>
<s5>45</s5>
</fC07>
<fN21><s1>251</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 97-0412076 INIST</NO>
<ET>Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study</ET>
<AU>MECO (G.); ALESSANDRI (A.); GIUSTINI (P.); BONIFATI (V.)</AU>
<AF>Department of Neurological Sciences, "La Sapienza" University/Roma/Italie (1 aut., 2 aut., 3 aut., 4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1997; Vol. 12; No. 4; Pp. 610-612; Bibl. 9 ref.</SO>
<LA>Anglais</LA>
<CC>002B02B03</CC>
<FD>Parkinson maladie; Psychose; Rispéridone; Antipsychotique; Trouble cognition; Chimiothérapie; Traitement; Homme; Etude longitudinale; Dose faible</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Psychopathologie</FG>
<ED>Parkinson disease; Psychosis; Risperidone; Antipsychotic; Cognitive disorder; Chemotherapy; Treatment; Human; Follow up study; Low dose</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Psychopathology</EG>
<GD>Aufbereiten</GD>
<SD>Parkinson enfermedad; Psicosis; Risperidona; Antipsicótico; Trastorno cognitivo; Quimioterapia; Tratamiento; Hombre; Estudio longitudinal; Dosis débil</SD>
<LO>INIST-20953.354000067729910220</LO>
<ID>97-0412076</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003210 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 003210 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:97-0412076
   |texte=   Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study

Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study

Source :

Descripteurs français

English descriptors

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri